3:05 PM
 | 
Oct 11, 2018
 |  BC Extra  |  Company News

Advisory panel narrowly rejects oliceridine for acute pain

FDA’s Anesthetic and Analgesic Drug Products Advisory Committee voted 8-7 against recommending approval of oliceridine (TRV130) from Trevena Inc. (NASDAQ:TRVN) to manage moderate to severe pain in adults for whom IV opioids are warranted.

Panelists who voted for approval thought oliceridine was at least as safe as morphine and might eventually prove to be safer, and could address unmet needs for patients allergic to or intolerant of morphine. They also thought it could be advantageous due to its fast onset and washout.

“The pharmacokinetics of this drug are attractive,” said Gregory Terman, director of the Acute Pain Service at the...

Read the full 476 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >